Favorable therapeutic efficacy of low‐density lipoprotein apheresis for nephrotic syndrome with impaired renal function
-
- Eri Muso
- Department of Food and Nutrition, Faculty of Contemporary Home Economics Kyoto Kacho University Kyoto Japan
-
- Soichi Sakai
- Siratori Clinic Tokyo Japan
-
- Youske Ogura
- Zenjinkai Ueno Hospital Tokyo Japan
-
- Susumu Yukawa
- Hakubunnkai Kodama Hospital Wakayama Japan
-
- Yoshiki Nishizawa
- University Public Corporation Osaka Osaka Japan
-
- Noriaki Yorioka
- Hiroshima Kidney Organization Hiroshima Japan
-
- Takao Saito
- Sanko Clinic Fukuoka Japan
-
- Masatoshi Mune
- Ryoshukai Fujii Hospital Kishiwada Japan
-
- Satoshi Sugiyama
- Kanayama Clinic Nagoya Japan
-
- Yasuhiko Iino
- Tokyo Medical School Tokyo Japan
-
- Tsutomu Hirano
- Diabetes Center Ebina General Hospital Ebina Japan
-
- Motoshi Hattori
- Department of Pediatric Nephrology Tokyo Women's Medical University Tokyo Japan
-
- Tsuyoshi Watanabe
- Tokyo‐kita Medical Center Tokyo Japan
-
- Hitoshi Yokoyama
- Department of Nephrology Kanazawa Medical University School of Medicine Uchinada Japan
-
- Hiroshi Sato
- Sendai Hospital of East Japan Railway Company Sendai Japan
-
- Shunya Uchida
- Department of Health Care Teikyo Heisei University Tokyo Japan
-
- Takashi Wada
- Department of Nephrology and Laboratory Medicine Institute of Medical, Pharmaceutical and Health Sciences, Faculty of Medicine, Kanazawa University Kanazawa Japan
-
- Tetsuo Shoji
- Department of Vascular Medicine Osaka City University Graduate School of Medicine Osaka Japan
-
- Hiroaki Oda
- Oda Clinic Hiroshima Japan
-
- Kiyoshi Mori
- School of Pharmaceutical Sciences, University of Shizuoka Shizuoka Japan
-
- Hideki Kimura
- Department of Clinical Laboratory University of Fukui Hospital Fukui Japan
-
- Osamu Ito
- Division of General Medicine and Rehabilitation Tohoku Medical and Pharmaceutical University Faculty of Medicine Sendai Japan
-
- Akira Nishiyama
- Department of Pharmacology, Faculty of Medicine Kagawa University Kagawa Japan
-
- Shoichi Maruyama
- Department of Nephrology Nagoya University Graduate School of Medicine Nagoya Japan
-
- Reiko Inagi
- Division of CKD Pathophysiology The University of Tokyo Graduate School of Medicine Tokyo Japan
-
- Shoichi Fujimoto
- Department of Hemovascular Medicine and Artificial Organs, Faculty of Medicine University of Miyazaki Miyazaki Japan
-
- Tatsuo Tsukamoto
- Department of Nephrology and Dialysis Kitano Hospital, Tazuke Kofukai Medical Research Institute Osaka Japan
-
- Yusuke Suzuki
- Department of Nephrology Juntendo University Faculty of Medicine Tokyo Japan
-
- Hirokazu Honda
- Department of Medicine, Division of Nephrology Showa University School of Medicine Tokyo Japan
-
- Tetsuya Babazono
- Department of Medicine, Diabetes Center, School of Medicine Tokyo Women's Medical University Tokyo Japan
-
- Kazuhiko Tsuruya
- Department of Nephrology Nara Medical University Kashiwara Japan
-
- Yukio Yuzawa
- Department of Nephrology Fujita Health University School of Medicine Toyoake Japan
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>Many reports have shown the therapeutic efficacy of LDL apheresis (LDL‐A) in drug‐resistant nephrotic syndrome (NS) for improvement of heavy proteinuria and severely impaired renal function. To obtain comprehensive results in a large number of cases, a post hoc analysis of the Prospective Observational survey on the Long‐Term Effects of the LDL‐Apheresis on the Drug Resistant Nephrotic Syndrome (POLARIS) study was performed by stratifying enrolled cases according to the pretreatment estimated glomerular filtration rate (eGFR) levels indicating normal (N) (≥60 ml/min/1.73 m<jats:sup>2</jats:sup>), moderately impaired (M) (≥30 to <60 ml/min/1.73 m<jats:sup>2</jats:sup>), and severely impaired (S) (<30 ml/min/1.73 m<jats:sup>2</jats:sup>) renal function. Significant improvements of proteinuria and renal function were found in Group N and, most interestingly, in Group M. A tendency for improvement in proteinuria was found in Group S. Most cases in all groups had not entered end‐stage renal disease at 2 years after LDL‐A treatment. These results suggest that LDL‐A has therapeutic efficacy even in cases in which renal function has declined to 30 ml/min/1.73 m<jats:sup>2</jats:sup>.</jats:p>
収録刊行物
-
- Therapeutic Apheresis and Dialysis
-
Therapeutic Apheresis and Dialysis 26 (1), 220-228, 2021-06-21
Wiley